Menu closed

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.

Immunology Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

For all other requests, please visit our Contact Lilly services.

Ebglyss^™ (lebrikizumab-lbkz)

Full Prescribing Information

Phase 1 Study of the Pharmacokinetics of Lebrikizumab Using a Pre-filled Syringe or Auto injector in Healthy Participants

Published Date: December 13, 2025

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Published Date: February 17, 2025

Lebrikizumab improves clinical manifestations, symptoms and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt study

Published Date: January 21, 2026

Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.

Published Date: November 08, 2025

Lebrikizumab rapidly reduces inflammatory biomarkers, correlating with clinical improvements in moderate-to-severe atopic dermatitis

Published Date: July 15, 2025

Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: Results from the phase 3b, open-label ADmirable study

Published Date: July 15, 2025

Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep Over 52 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials

Published Date: July 2, 2025

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Published Date: June 25, 2025

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Published Date: February 17, 2025

Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).

Published Date: January 9, 2025

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.

Published Date: January 6, 2025

Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)

Published Date: December 13, 2024

Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J).

Published Date: October 23, 2024

Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).

Published Date: September 9, 2024

Lebrikizumab monotherapy improves itch and sleep interference due to itch, which impacts quality of life in two Phase 3 trials

Published Date: April 28, 2024

Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.

Published Date: March 6, 2024

Lebrikizumab Improved Itch and Reduced the Extent of Itch Interference on Sleep in Patients with Moderate-to-Severe Atopic Dermatitis: Two Randomized Placebo-Controlled Phase 3 Trials

Published Date: November 10, 2023

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.

Published Date: June 15, 2023

Efficacy And Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials

Published Date: March 30, 2023

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Published Date: March 15, 2023

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).

Published Date: January 12, 2023

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

Published Date: July 14, 2022

No Publication Journals

Olumiant^® (baricitinib)

Full Prescribing Information

No Publication Journals

Long-term efficacy of continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2

Published Date: November 26, 2025

Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

Published Date: February 23, 2024

Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.

Published Date: August 9, 2023

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)

Published Date: April 22, 2023

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.

Published Date: May 24, 2022

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 and up to 4.6 years treatment: final integrated analysis of 8 clinical trials.

Published Date: September 19, 2025

Neutrophil activation markers can predict rheumatoid arthritis treatment response to the Janus Kinase 1/2 inhibitor baricitinib

Published Date: December 12, 2024

Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

Published Date: February 23, 2024

Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.

Published Date: August 9, 2023

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.

Published Date: June 21, 2023

Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)

Published Date: April 22, 2023

Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).

Published Date: April 13, 2023

Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.

Published Date: April 10, 2023

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.

Published Date: April 3, 2023

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).

Published Date: March 31, 2023

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).

Published Date: February 24, 2023

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis in 4 phase 3 clinical studies

Published Date: January 20, 2023

Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.

Published Date: December 14, 2022

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials

Published Date: December 7, 2022

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.

Published Date: November 17, 2022

Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes

Published Date: October 21, 2022

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): A Clinical Outcome Measure for the Severity of Atopic Dermatitis

Published Date: August 21, 2022

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Published Date: May 23, 2022

Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis with Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial (BREEZE-AD4)

Published Date: May 3, 2022

Rapid Improvement in Skin Pain Severity and its Impact on Quality of Life in Adult Patients with Moderate-to-Severe Atopic Dermatitis from a Double-blind, Placebo-controlled Baricitinib Phase 3 Study

Published Date: March 31, 2022

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Published Date: March 26, 2022

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

Published Date: March 9, 2022

Baricitinib further enhances disease modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

Published Date: February 23, 2022

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

Published Date: February 3, 2022

Symptom Onset Relief in Atopic Dermatitis Patients Treated with Baricitinib in United States Trial

Published Date: January 28, 2022

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.

Published Date: January 18, 2022

Pain reduction in rheumatoid arthritis patients who use opioids: a post-hoc analysis of phase 3 trials of baricitinib

Published Date: December 16, 2021

Psychometric properties of the Itch Numeric Rating Scale, Skin Pain Numeric Rating Scale, and Atopic Dermatitis Sleep Scale in patients with moderate-to-severe atopic dermatitis

Published Date: October 23, 2021

Radiographic progression of structural joint damage over 5 years of Baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND

Published Date: September 21, 2021

Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial

Published Date: September 1, 2021

Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy

Published Date: June 28, 2021

Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study.

Published Date: December 12, 2025

RA-BE-REAL Effectiveness, resource utilization and cost of rheumatoid arthritis patients treated with baricitinib or other DMARDs in Spain

Published Date: July 8, 2025

Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study.

Published Date: April 7, 2025

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.

Published Date: September 28, 2023

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Published Date: September 27, 2023

Comparing the Burden of Illness in Patients

Published Date: March 29, 2023

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: A 6-Month Interim Analysis

Published Date: October 13, 2022

The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata.

Published Date: March 29, 2022

Cohort profile: patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)

Published Date: February 16, 2022

Validation Study of Algorithms to Identify Malignant Tumors and Serious Infections in a Japanese Administrative Healthcare Database

Published Date: January 7, 2022

Prevalence of renal impairment in a US commercially insured rheumatoid arthritis population: a retrospective analysis

Published Date: July 28, 2021

Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims

Published Date: July 22, 2021

Omvoh^® (mirikizumab)

Full Prescribing Information

One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants.

Published Date: November 28, 2025

Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants.

Published Date: September 3, 2025

Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials.

Published Date: March 21, 2025

Safety and Pharmacokinetics of Single-Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study.

Published Date: September 4, 2024

Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately to Severely Active Crohn's Disease: Results From Two Randomized Studies

Published Date: August 13, 2025

Mirikizumab Pharmacokinetics and Exposure–Response in Pediatric Patients with Moderate-to-Severe Ulcerative Colitis.

Published Date: December 18, 2024

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study.

Published Date: August 2, 2024

Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.

Published Date: May 26, 2024

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Published Date: November 20, 2023

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.

Published Date: August 23, 2023

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.

Published Date: August 18, 2023

Development of a Novel Ulcerative Colitis Endoscopic Mayo Score Prediction Model using Machine Learning

Published Date: June 16, 2023

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.

Published Date: March 31, 2023

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.

Published Date: March 7, 2023

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.

Published Date: June 3, 2022

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.

Published Date: November 19, 2021

Novel methodology comparing two assay formats for the assessment of immunogenicity from clinical trial samples.

Published Date: July 22, 2021

Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately to Severely Active Crohn's Disease: Results From Two Randomized Studies

Published Date: August 13, 2025

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study.

Published Date: July 14, 2025

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.

Published Date: July 12, 2025

Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.

Published Date: July 1, 2025

Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis.

Published Date: June 14, 2025

Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.

Published Date: June 10, 2025

Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.

Published Date: March 13, 2025

Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.

Published Date: March 12, 2025

A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease.

Published Date: February 17, 2025

The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease.

Published Date: February 3, 2025

Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials.

Published Date: January 8, 2025

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.

Published Date: November 21, 2024

Psychometric evaluation of the Functional Assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn's disease.

Published Date: November 13, 2024

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Published Date: October 25, 2024

Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.

Published Date: October 4, 2024

Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.

Published Date: June 13, 2024

Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.

Published Date: May 26, 2024

Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.

Published Date: April 25, 2024

Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: Results from the LUCENT-3 open-label extension study

Published Date: March 9, 2024

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

Published Date: January 25, 2024

Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.

Published Date: January 6, 2024

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.

Published Date: November 7, 2023

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.

Published Date: August 23, 2023

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

Published Date: August 21, 2023

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Published Date: June 29, 2023

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.

Published Date: April 14, 2023

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.

Published Date: December 13, 2022

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).

Published Date: December 1, 2022

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

Published Date: November 5, 2022

Disease burden of patients with moderate to severe ulcerative colitis: A French multicenter real-life study (THEFAR).

Published Date: September 5, 2024

Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need from the CorEvitas Inflammatory Bowel Disease Registry

Published Date: April 5, 2023

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease Registry

Published Date: March 8, 2022

Taltz^® (ixekizumab)

Full Prescribing Information

Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.

Published Date: April 22, 2022

No Publication Journals

Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging.

Published Date: January 6, 2026

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.

Published Date: July 22, 2025

Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level

Published Date: May 9, 2025

Synergistic improvements in synovitis and enthesitis and improvements in patient-reported outcomes, including health-related quality-of-life, for patients with psoriatic arthritis treated with ixekizumab

Published Date: February 27, 2025

BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis.

Published Date: January 29, 2025

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

Published Date: November 13, 2024

Improvement in Spinal Pain at Night and its Impact on Long-Term Outcomes in Radiographic Axial Spondyloarthritis: Results from Ixekizumab COAST-V randomised Trial

Published Date: October 23, 2024

Treatment-Emergent Candida Infections in Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis Treated with Ixekizumab: An Integrated Safety Analysis of 25 Clinical Studies

Published Date: September 12, 2024

Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas

Published Date: July 26, 2024

Early Clinical Response Associates with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis

Published Date: July 15, 2024

Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials

Published Date: May 30, 2024

Ixekizumab-treated patients with complete scalp psoriasis clearance by week 60 demonstrate long-term sustained improvements in clinical and patient-reported outcomes and quality of life through 5 years

Published Date: April 22, 2024

Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).

Published Date: October 19, 2023

Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Published Date: September 27, 2023

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

Published Date: August 24, 2023

Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients with Radiographic Axial Spondyloarthritis in Ixekizumab Trials

Published Date: February 22, 2023

Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST programme

Published Date: February 15, 2023

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

Published Date: October 14, 2022

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.

Published Date: September 13, 2022

Efficacy and Safety of Ixekizumab in Chinese Patients with moderate-to-Severe Plaque Psoriasis: Results from a Phase 3 Study

Published Date: July 26, 2022

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.

Published Date: July 19, 2022

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: data from 17 Clinical Trials with Over 17,000 Patient-Years of Exposure

Published Date: May 31, 2022

Consistency of efficacy for ixekizumab in patients with plaque psoriasis: subgroup analysis by European country-specific reimbursement requirements

Published Date: May 27, 2022

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

Published Date: April 13, 2022

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis

Published Date: March 15, 2022

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

Published Date: February 21, 2022

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

Published Date: December 20, 2021

Ixekizumab Provides Persistent Improvements in Health-Related Quality of Life and Sexual Health Associated with Moderate-to-Severe Genital Psoriasis During a 52-Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Published Date: December 6, 2021

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.

Published Date: December 1, 2021

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.

Published Date: September 1, 2021

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate-to-severe psoriasis: a post-hoc analysis from IXORA-PEDS

Published Date: July 30, 2021

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study

Published Date: February 3, 2026

Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study

Published Date: December 1, 2025

Comparative effectiveness and durability of biologics in clinical practice: Month 24 outcomes from the international, observational Psoriasis Study of Health Outcomes (PSoHO)

Published Date: July 24, 2025

Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Postmarketing Surveillance

Published Date: March 13, 2025

Published Date: February 27, 2025

Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from an International Observational Psoriasis Study of Health Outcomes (PSoHO)

Published Date: November 25, 2024

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.

Published Date: September 24, 2024

Association Between Disease Duration and Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis Treated With Biologics in a Real-world Setting: Results at Week 12 From the Psoriasis Study of Health Outcomes (PSoHO)

Published Date: May 23, 2024

The safety of ixekizumab in Chinese adults with moderate-to-severe plaque psoriasis: analyses from a prospective, single-arm, multicenter, 12-week observational study

Published Date: April 30, 2024

Effectiveness of ixekizumab in Chinese patients with moderate-severe plaque psoriasis with special area involvement: Sub-analysis of a prospective, multi-center, observational real-world study

Published Date: March 27, 2024

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).

Published Date: February 9, 2024

Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).

Published Date: December 22, 2023

Effectiveness of biologics, patient-reported outcomes, and clinical photography in a subset of patients with moderate-to-severe psoriasis: Week 12 results from the Psoriasis Study of Health Outcomes (PSoHO)

Published Date: October 20, 2023

Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study.

Published Date: October 12, 2023

Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).

Published Date: June 29, 2023

Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort.

Published Date: June 21, 2023

Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.

Published Date: May 20, 2023

Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population.

Published Date: March 2, 2023

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.

Published Date: February 25, 2023

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting

Published Date: December 14, 2022

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.

Published Date: September 26, 2022

Comparative Effectiveness of Biologics in Clinical Practice: Week 12 Primary Outcomes from an International Observational Psoriasis Study of Health Outcomes (PSoHO).

Published Date: June 29, 2022

Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.

Published Date: June 6, 2022

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: data from 17 Clinical Trials with Over 17,000 Patient-Years of Exposure

Published Date: May 31, 2022

Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.

Published Date: March 28, 2022

Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population

Published Date: March 22, 2022

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.

Published Date: March 13, 2022

Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry

Published Date: February 21, 2022

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.

Published Date: January 31, 2022

Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study

Published Date: January 20, 2022

Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting

Published Date: January 19, 2022

Ixekizumab: 80 mg Q2W Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis & Erythrodermic Psoriasis

Published Date: December 29, 2021

Understanding patient demographic, clinical, and treatment history of patients newly initiating ixekizumab: Findings from the Corrona Psoriasis Registry

Published Date: December 23, 2021

Comparison of Real-world Treatment Patterns among Biologic-experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab over 18 Months

Published Date: October 15, 2021

Treatment Satisfaction and Decision Making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from the ArthritisPower Registry

Published Date: October 10, 2021

Clinical and Quality of Life Outcomes among Ixekizumab Treated Psoriasis Patients in a Real-World Setting

Published Date: October 6, 2021

Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study

Published Date: September 22, 2021

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.

Published Date: September 13, 2021

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.

Published Date: September 1, 2021

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

Published Date: July 8 2021

Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.

Published Date: June 6, 2021

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial

Published Date: June 6, 2021

Can't find what you're looking for? Contact us for answers to your medical questions.

Copyright
Terms of Use
Privacy Statement
Consumer Health Privacy Notice
Accessibility Statement
Sitemap

This site is intended for US Healthcare Professionals only.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Your Privacy Choices

Cookie Settings

Immunology Journal Publications

Ebglyss: Phase I Phase I

Ebglyss: Phase II Phase II

Ebglyss: Phase III Phase III

Ebglyss: Phase IV & Real World Evidence (No Publications Available) Phase IV & Real World Evidence (No Publications Available)

Olumiant: Phase I (No Publications Available) Phase I (No Publications Available)

Olumiant: Phase II Phase II

Olumiant: Phase III Phase III

Olumiant: Phase IV & Real World Evidence Phase IV & Real World Evidence

Omvoh: Phase I Phase I

Omvoh: Phase II Phase II

Omvoh: Phase III Phase III

Omvoh: Phase IV & Real World Evidence Phase IV & Real World Evidence

Taltz: Phase I Phase I

Taltz: Phase II (No Publications Available) Phase II (No Publications Available)

Taltz: Phase III Phase III

Taltz: Phase IV & Real World Evidence Phase IV & Real World Evidence